Investment Rating - The report gives a "Buy" rating for the company [3]. Core Views - The company is expected to see significant revenue growth from 2025 to 2027, with projected revenues of CNY 5.66 billion, CNY 7.19 billion, and CNY 9.24 billion, representing year-on-year growth rates of 27.8%, 27.0%, and 28.6% respectively. Net profit attributable to the parent company is forecasted to be CNY 1.79 billion, CNY 2.26 billion, and CNY 2.89 billion for the same years, with growth rates of 32.5%, 26.3%, and 27.6% respectively [3][4]. Company Overview - The company, established in 2003, focuses on the research, development, production, and sales of medical endoscopic instruments and optical products. It integrates optical technology with various fields including medicine, industry, and laser technology [15][24]. - The company has a complete industrial chain from system design to optical processing and system integration, providing high-quality products and services for medical and optical fields [15]. Financial Performance - In 2024, the company achieved a revenue of CNY 4.43 billion, a decrease of 5.90% year-on-year, and a net profit of CNY 1.35 billion, down 7.11% year-on-year. However, in Q1 2025, the company reported a revenue of CNY 1.47 billion, a year-on-year increase of 24.86%, and a net profit of CNY 0.47 billion, up 21.45% year-on-year [18][20]. - The company's gross margin slightly improved to 64.51% in 2024, while the net margin was 30.20% [22]. Market Potential - The report highlights the significant growth potential in the fluorescence endoscope market, with the Chinese hard endoscope market nearing CNY 100 billion in 2024 and a growing domestic production rate [41][42]. - The global fluorescence endoscope market is expected to grow rapidly, with a projected compound annual growth rate of 24.3% [44]. Product Development - The company has successfully launched the new generation of fluorescence endoscopes, which are expected to drive sales growth. The N780 4K fluorescence endoscope system is anticipated to lead market sales [4][25]. - The company has established strong partnerships with major international medical device manufacturers, enhancing its market position [35].

报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2024年4月24日， 海泰新光 发布2024年年报及2025年一季报。 # 2024年拆分 医用内窥镜器械行业收入 3.45亿 元 （相比上年度下降7.04%）； 光学行业收入 0.95亿 元 （相比上年度下 降1.80%）。 另外，ODM业务收入2.81亿元，占比63.81%；OEM业务收入0.94亿元，占比21.39%；自主品牌产品收入 0.65亿元，占比14.80%。受国内医疗反腐因素影响，2024年公司自主品牌销售虽同比略有增长，但自主品 牌中整机产品销售同比增长2,276.71万元，同比增长显著。 (1)2024年，受美国客户去库存影响，公司前三季度海外营业收入下降明显。第四季度随着客户库存降到低 位，发货相比2023年同期大幅增长。延续客户需求增长趋势，公司海外业务收入会进一步增长； (2)2024年，公司国内整机业务推进良好，同比增长显著； # 财报数据 2024年公司实现收入 4.43亿 元，同比下降 5.90% ；实现归母净利润 1.35亿 元， 同比下降7.11%；实现扣 非归母净利润1.29亿元，同比下降 ...